to sustain and raise market share for products within the Restylane product family, an anti-ageing treatment that rivals Allergan Inc's (AGN.N "This will result in higher costs for marketing, sales organization and product development relative to Q-Med's...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to UPDATE 1-Swedish bid target Q-Med downbeat on margins
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account